Trial Profile
A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Pharmacodynamics
- 31 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2024.
- 13 Oct 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2024.